

Martha Nowosielski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6256442/publications.pdf>

Version: 2024-02-01

29
papers

1,736
citations

567281

15
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

3388
citing authors

#	ARTICLE	IF	CITATIONS
1	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740.	10.7	271
2	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	7.3	236
3	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
4	¹⁸ F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 856-864.	5.0	162
5	Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598.	1.2	106
6	Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. <i>Neurology</i> , 2014, 82, 1684-1692.	1.1	101
7	ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. <i>Neuroradiology</i> , 2011, 53, 291-302.	2.2	90
8	Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. <i>Neuro-Oncology</i> , 2015, 17, 151-159.	1.2	90
9	Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1139-1147.	1.2	89
10	An Intra-Individual Comparison of MRI, [18F]-FET and [18F]-FLT PET in Patients with High-Grade Gliomas. <i>PLoS ONE</i> , 2014, 9, e95830.	2.5	71
11	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
12	Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2009, 11, 22.	3.3	38
13	Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology. <i>PLoS ONE</i> , 2015, 10, e0121220.	2.5	36
14	Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1673-1679.	1.2	36
15	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	7.3	19
16	Imaging Criteria in Neuro-oncology. <i>Seminars in Neurology</i> , 2018, 38, 024-031.	1.4	17
17	The emerging role of advanced neuroimaging techniques for brain metastases. <i>Chinese Clinical Oncology</i> , 2015, 4, 23.	1.2	13
18	Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline. <i>Journal of Neuroscience Methods</i> , 2019, 311, 215-221.	2.5	12

#	ARTICLE	IF	CITATIONS
19	How to facilitate early diagnosis of CNS involvement in malignant lymphoma. Expert Review of Hematology, 2016, 9, 1081-1091.	2.2	10
20	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
21	Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. Anticancer Research, 2015, 35, 4955-60.	1.1	7
22	Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis – safety analysis and validation of the EANO-ESMO classification. Strahlentherapie Und Onkologie, 2022, 198, 475-483.	2.0	7
23	Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation. Current Oncology, 2021, 28, 5041-5053.	2.2	6
24	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. Cancers, 2022, 14, 1579.	3.7	6
25	Perampanel in brain tumor and SMART-syndrome related epilepsy – A single institutional experience. Journal of the Neurological Sciences, 2021, 423, 117386.	0.6	4
26	ADC textural features in patients with single brain metastases improve clinical risk models. Clinical and Experimental Metastasis, 2022, 39, 459-466.	3.3	3
27	Bilateral medial medullary syndrome following anterior screw fixation of type 2 odontoid fracture, a case report of two patients. Spinal Cord Series and Cases, 2021, 7, 101.	0.6	1
28	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. Neuro-Oncology, 2021, 23, vi130-vi130.	1.2	0
29	NCMP-14. WHOLE BRAIN RADIOTHERAPY COMBINED WITH INTRATHECAL LIPOSOMAL CYTARABINE FOR LEPTOMENINGEAL METASTASIS – A SAFETY ANALYSIS AND VALIDATION OF THE EANO-ESMO CLASSIFICATION. Neuro-Oncology, 2021, 23, vi149-vi150.	1.2	0